Minerva Neurosciences (NERV) Return on Capital Employed (2014 - 2026)
Minerva Neurosciences posted quarterly Return on Capital Employed of 30.46% for Q1 2026, up 2729.0% year-on-year from 1.08% in Q1 2025, and down 22.48% on a QoQ basis from 24.86% in Q4 2025.
Minerva Neurosciences (NERV) has 13 years of Return on Capital Employed data on file, last reported at 30.46% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 2729.0% year-over-year to 30.46%; the trailing twelve-month figure through Mar 2026 stood at 30.46% (up 2729.0% YoY), and the FY2025 full-year result was 23.14%, up 2631.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 30.46%, down from 24.86% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 24.86% in Q4 2025 and bottomed at 69.04% in Q3 2022.
- The 5-year median for Return on Capital Employed is 55.09% (2025), against an average of 50.15%.
- The widest annual swing landed in 2022, when Return on Capital Employed tumbled 7304 bps; it then surged 3503 bps in 2023.
- A 5-year view of Return on Capital Employed shows it stood at 45.02% in 2022, then advanced by 9 bps to 40.79% in 2023, then sank by 44 bps to 58.83% in 2024, then jumped by 58 bps to 24.86% in 2025, then dropped by 22 bps to 30.46% in 2026.
- The last three Return on Capital Employed figures came in at 30.46% (Q1 2026), 24.86% (Q4 2025), and 55.09% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | -30.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.46% |
| Dec 31, 2025 | -24.86% |
| Sep 30, 2025 | -55.09% |
| Jun 30, 2025 | -55.59% |
| Mar 31, 2025 | -57.74% |
| Dec 31, 2024 | -58.83% |
| Sep 30, 2024 | -61.14% |
| Jun 30, 2024 | -59.30% |
| Mar 31, 2024 | -48.07% |
| Dec 31, 2023 | -40.79% |
| Sep 30, 2023 | -34.02% |
| Jun 30, 2023 | -35.06% |
| Mar 31, 2023 | -44.44% |
| Dec 31, 2022 | -45.02% |
| Sep 30, 2022 | -69.04% |
| Jun 30, 2022 | -68.11% |
| Mar 31, 2022 | -64.92% |
| Dec 31, 2021 | -53.67% |
| Sep 30, 2021 | -31.81% |
| Jun 30, 2021 | -30.60% |
| Mar 31, 2021 | 8.12% |
| Dec 31, 2020 | 3.17% |
| Sep 30, 2020 | -38.51% |
| Jun 30, 2020 | -48.96% |
| Mar 31, 2020 | -108.79% |
| Dec 31, 2019 | -86.68% |
| Sep 30, 2019 | -54.07% |
| Jun 30, 2019 | -47.05% |
| Mar 31, 2019 | -43.35% |
| Dec 31, 2018 | -36.63% |
| Sep 30, 2018 | -31.37% |
| Jun 30, 2018 | -28.65% |
| Mar 31, 2018 | -25.37% |
| Dec 31, 2017 | -22.65% |
| Sep 30, 2017 | -26.94% |
| Jun 30, 2017 | -32.29% |
| Mar 31, 2017 | -27.17% |
| Dec 31, 2016 | -23.65% |
| Sep 30, 2016 | -21.75% |
| Jun 30, 2016 | -23.31% |
| Mar 31, 2016 | -34.33% |
| Dec 31, 2015 | -32.38% |
| Sep 30, 2015 | -28.62% |
| Jun 30, 2015 | -49.65% |
| Mar 31, 2015 | -72.01% |
| Dec 31, 2014 | -81.43% |
| Sep 30, 2014 | -82.50% |